HUP0400697A3 - Silensed anti-cd28 antibodies and use thereof - Google Patents

Silensed anti-cd28 antibodies and use thereof

Info

Publication number: HUP0400697A3
Authority: HU; Hungary
Prior art keywords: silensed; antibodies; silensed anti
Prior art date: 2000-12-14

Application number

HU0400697A

Other languages

English (en)

Original Assignee

Astellas Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-14

Filing date

2001-12-14

Publication date

2007-05-02

2001-12-14 Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc

2004-06-28 Publication of HUP0400697A2 publication Critical patent/HUP0400697A2/hu

2007-05-02 Publication of HUP0400697A3 publication Critical patent/HUP0400697A3/hu

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Transplantation (AREA)
Surgery (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

HU0400697A 2000-12-14 2001-12-14 Silensed anti-cd28 antibodies and use thereof HUP0400697A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US25515500P	2000-12-14	2000-12-14
PCT/US2001/047955 WO2002047721A1 (en)	2000-12-14	2001-12-14	Silensed anti-cd28 antibodies and use thereof

Publications (2)

Publication Number	Publication Date
HUP0400697A2 HUP0400697A2 (hu)	2004-06-28
HUP0400697A3 true HUP0400697A3 (en)	2007-05-02

Family

ID=22967074

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HU0400697A HUP0400697A3 (en)	2000-12-14	2001-12-14	Silensed anti-cd28 antibodies and use thereof

Country Status (18)

Country	Link
EP (1)	EP1341553A4 (hu)
JP (1)	JP2004515243A (hu)
KR (1)	KR20040020866A (hu)
CN (1)	CN1272345C (hu)
AR (1)	AR031924A1 (hu)
AU (2)	AU2002226086C1 (hu)
BR (1)	BR0116686A (hu)
CA (1)	CA2432736A1 (hu)
CZ (1)	CZ20031909A3 (hu)
HU (1)	HUP0400697A3 (hu)
IL (1)	IL156262A0 (hu)
MX (1)	MXPA03005327A (hu)
NO (1)	NO20032542L (hu)
NZ (1)	NZ526569A (hu)
PL (1)	PL363239A1 (hu)
RU (1)	RU2261723C2 (hu)
WO (1)	WO2002047721A1 (hu)
ZA (1)	ZA200305384B (hu)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20080095774A1 (en) *	2001-02-16	2008-04-24	Wyeth	Agents and Methods for Specifically Blocking CD28-Mediated Signaling
US7531168B2 (en)	2001-02-16	2009-05-12	Genetics Institute Llc	Method for downmodulating immune response in type I diabetes
EP1909831A4 (en)	2005-06-14	2013-02-20	Amgen Inc	SELF-BUFFING PROTEIN FORMULATIONS
FR2951176A1 (fr) *	2009-10-09	2011-04-15	Tcl Pharma	Ligands monovalents du recepteur cd28 humain
PL2536764T3 (pl) *	2010-02-18	2018-12-31	Ose Immunotherapeutics	Humanizowane przeciwciała anty-CD28
KR102446838B1 (ko)	2016-10-21	2022-09-26	암젠 인크	약학적 제형 및 그의 제조 방법
CA3103629A1 (en)	2018-06-15	2019-12-19	Flagship Pioneering Innovations V, Inc.	Increasing immune activity through modulation of postcellular signaling factors
CA3130348A1 (en) *	2019-03-14	2020-09-17	Motti HAKIM	A method for immunosuppression
MA55805A (fr)	2019-05-03	2022-03-09	Flagship Pioneering Innovations V Inc	Métodes de modulation de l'activité immunitaire
EP4076434A1 (en)	2019-12-17	2022-10-26	Flagship Pioneering Innovations V, Inc.	Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
CA3184366A1 (en)	2020-06-29	2022-01-06	Darby Rye Schmidt	Viruses engineered to promote thanotransmission and their use in treating cancer
KR20230166150A (ko)	2020-08-19	2023-12-06	젠코어 인코포레이티드	항-cd28 조성물
AU2022246895A1 (en)	2021-03-31	2023-10-19	Flagship Pioneering Innovations V, Inc.	Thanotransmission polypeptides and their use in treating cancer
EP4363059A1 (en)	2021-06-29	2024-05-08	Flagship Pioneering Innovations V, Inc.	Immune cells engineered to promote thanotransmission and uses thereof
JP2025508827A (ja)	2022-02-23	2025-04-10	ゼンコアインコーポレイテッド	抗ｃｄ２８×抗ｐｓｍａ抗体
WO2024040195A1 (en)	2022-08-17	2024-02-22	Capstan Therapeutics, Inc.	Conditioning for in vivo immune cell engineering
EP4598946A1 (en)	2022-10-05	2025-08-13	Flagship Pioneering Innovations V, Inc.	Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024148336A1 (en) *	2023-01-06	2024-07-11	Igm Biosciences, Inc.	T cell costimulatory multimeric binding molecules and uses thereof
US20240269251A1 (en)	2023-01-09	2024-08-15	Flagship Pioneering Innovations V, Inc.	Genetic switches and their use in treating cancer
US12311033B2 (en)	2023-05-31	2025-05-27	Capstan Therapeutics, Inc.	Lipid nanoparticle formulations and compositions
WO2025076127A1 (en)	2023-10-05	2025-04-10	Capstan Therapeutics, Inc.	Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en)	2023-10-05	2025-04-10	Capstan Therapeutics, Inc.	Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250302763A1 (en)	2024-02-22	2025-10-02	Capstan Therapeutics, Inc.	Immune engineering amplification
WO2025217452A1 (en)	2024-04-11	2025-10-16	Capstan Therapeutics, Inc.	Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en)	2024-04-11	2025-10-16	Capstan Therapeutics, Inc.	Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5521288A (en) *	1990-03-26	1996-05-28	Bristol-Myers Squibb Company	CD28IG fusion protein

2001
- 2001-12-14 RU RU2003121231/15A patent/RU2261723C2/ru not_active IP Right Cessation
- 2001-12-14 MX MXPA03005327A patent/MXPA03005327A/es unknown
- 2001-12-14 JP JP2002549291A patent/JP2004515243A/ja not_active Withdrawn
- 2001-12-14 EP EP01995504A patent/EP1341553A4/en not_active Withdrawn
- 2001-12-14 HU HU0400697A patent/HUP0400697A3/hu unknown
- 2001-12-14 PL PL01363239A patent/PL363239A1/xx not_active Application Discontinuation
- 2001-12-14 CA CA002432736A patent/CA2432736A1/en not_active Abandoned
- 2001-12-14 AR ARP010105828A patent/AR031924A1/es unknown
- 2001-12-14 KR KR10-2003-7007798A patent/KR20040020866A/ko not_active Ceased
- 2001-12-14 IL IL15626201A patent/IL156262A0/xx unknown
- 2001-12-14 CZ CZ20031909A patent/CZ20031909A3/cs unknown
- 2001-12-14 AU AU2002226086A patent/AU2002226086C1/en not_active Ceased
- 2001-12-14 WO PCT/US2001/047955 patent/WO2002047721A1/en not_active Ceased
- 2001-12-14 BR BR0116686-7A patent/BR0116686A/pt not_active IP Right Cessation
- 2001-12-14 CN CNB018226361A patent/CN1272345C/zh not_active Expired - Fee Related
- 2001-12-14 AU AU2608602A patent/AU2608602A/xx active Pending
- 2001-12-14 NZ NZ526569A patent/NZ526569A/en unknown
2003
- 2003-06-05 NO NO20032542A patent/NO20032542L/no not_active Application Discontinuation
- 2003-07-11 ZA ZA200305384A patent/ZA200305384B/en unknown

Also Published As

Publication number	Publication date
AR031924A1 (es)	2003-10-08
ZA200305384B (en)	2004-10-11
KR20040020866A (ko)	2004-03-09
EP1341553A1 (en)	2003-09-10
NZ526569A (en)	2005-07-29
RU2261723C2 (ru)	2005-10-10
WO2002047721A1 (en)	2002-06-20
HUP0400697A2 (hu)	2004-06-28
IL156262A0 (en)	2004-01-04
CA2432736A1 (en)	2002-06-20
JP2004515243A (ja)	2004-05-27
BR0116686A (pt)	2003-12-30
AU2608602A (en)	2002-06-24
AU2002226086B2 (en)	2005-08-25
RU2003121231A (ru)	2005-02-10
CN1489473A (zh)	2004-04-14
NO20032542D0 (no)	2003-06-05
AU2002226086C1 (en)	2006-03-09
MXPA03005327A (es)	2004-12-03
CN1272345C (zh)	2006-08-30
PL363239A1 (en)	2004-11-15
CZ20031909A3 (cs)	2003-11-12
NO20032542L (no)	2003-08-07
EP1341553A4 (en)	2004-07-28

Publication	Publication Date	Title
AU2608602A (en)	2002-06-24	Silensed anti-cd28 antibodies and use thereof
TWI316088B (en)	2009-10-21	Anti-tnf alpha antibodies and their uses
IL151853A (en)	2009-09-01	Multivalent antibodies and uses thereof
GB0029360D0 (en)	2001-01-17	Humanised antibodies and uses thereof
EP1551447A4 (en)	2007-03-07	ANTI-ADDL ANTIBODIES AND USES THEREOF
IL154325A (en)	2010-12-30	Isolated anti-il-12 antibody and composition comprising the same
HUP0302128A3 (en)	2005-11-28	Anti-dual integrin antibodies, compositions, methods and uses
GB9927332D0 (en)	2000-01-12	Novel antibody and uses thereof
PL366305A1 (en)	2005-01-24	Substituted 2-anilino-benzimidazoles and the use thereof as nhe-inhibitors
GB0007333D0 (en)	2000-05-17	Novel compounds and their manufacture and use
AU2003219093A8 (en)	2003-10-08	Anti-hpv-16 e7 antibodies and their use
IL172510A0 (en)	2006-04-10	Antibodies and uses thereof
IL166063A0 (en)	2006-01-15	Antibodies and uses thereof
GB0026134D0 (en)	2000-12-13	Peptides and their use
GB0021497D0 (en)	2000-10-18	Compounds and their use
GB0007530D0 (en)	2000-05-17	Trityl-type compounds and their use
GB0005071D0 (en)	2000-04-26	Antibodies
GB0003527D0 (en)	2000-04-05	Antibodies
GB0227080D0 (en)	2002-12-24	Antibodies and uses thereof
GB0002559D0 (en)	2000-03-29	Virulencegene and protein and their use
GB0017139D0 (en)	2000-08-30	Human monoclonal antibodies
GB0016824D0 (en)	2000-08-30	Human monoclonal antibodies
AU2002338089A1 (en)	2003-04-07	Antibody and use thereof
GB0026136D0 (en)	2000-12-13	Peptides and their use
GB0018148D0 (en)	2000-09-13	Peptides and their use

Legal Events

Date	Code	Title	Description
2006-03-28	GB9A	Succession in title	Owner name: ASTELLAS PHARMA INC., JP Free format text: FORMER OWNER(S): FUJISAWA PHARMACEUTICAL CO., LTD., JP
2007-09-28	FD9A	Lapse of provisional protection due to non-payment of fees

Date

Code

Title

Description

2006-03-28

GB9A

Succession in title

Owner name: ASTELLAS PHARMA INC., JP

Free format text: FORMER OWNER(S): FUJISAWA PHARMACEUTICAL CO., LTD., JP

2007-09-28

FD9A

Lapse of provisional protection due to non-payment of fees